Detalhe da pesquisa
1.
Inhibition of Prekallikrein for Hereditary Angioedema.
N Engl J Med
; 386(11): 1026-1033, 2022 03 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35294812
2.
Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 401(10382): 1079-1090, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36868261
3.
A phase 2 open-label extension study of prekallikrein inhibition with donidalorsen for hereditary angioedema.
Allergy
; 79(3): 724-734, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38009241
4.
Berotralstat (BCX7353) is a novel oral prophylactic treatment for hereditary angioedema: Review of phase II and III studies.
Allergy Asthma Proc
; 42(4): 274-282, 2021 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34127176
5.
Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor.
N Engl J Med
; 376(12): 1131-1140, 2017 03 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-28328347
6.
Hereditary angioedema: Differential diagnosis, diagnostic tests, and family screening.
Allergy Asthma Proc
; 41(Suppl 1): S22-S25, 2020 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33109321
7.
Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial.
JAMA
; 320(20): 2108-2121, 2018 11 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30480729
8.
Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children.
J Pediatr
; 162(5): 1017-22.e1-2, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23312695
9.
Recognition and Management of Hereditary Angioedema: Best Practices for Dermatologists.
Dermatol Ther (Heidelb)
; 11(5): 1829-1838, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34460082
10.
Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema.
Pediatr Allergy Immunol Pulmonol
; 33(3): 136-141, 2020 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32953229
11.
Indirect comparison of intravenous vs. subcutaneous C1-inhibitor placebo-controlled trials for routine prevention of hereditary angioedema attacks.
Allergy Asthma Clin Immunol
; 15: 13, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30899278
12.
Treatment patterns and healthcare resource utilization among patients with hereditary angioedema in the United States.
Orphanet J Rare Dis
; 13(1): 180, 2018 10 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30314518
13.
Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema.
J Allergy Clin Immunol Pract
; 6(5): 1733-1741.e3, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29391286
14.
Escalating doses of C1 esterase inhibitor (CINRYZE) for prophylaxis in patients with hereditary angioedema.
J Allergy Clin Immunol Pract
; 2(1): 77-84, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24565773
15.
Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings.
J Allergy Clin Immunol Pract
; 7(6): 2035-2038, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30660873